Aardvark Therapeutics, Inc. (AARD)

In the past six months, Aardvark Therapeutics has experienced several events impacting its stock price. In November 2025, the company presented data at ObesityWeek 2025, announced an inducement grant, reported its Third Quarter 2025 financial results with an EPS of -$0.75, and Cantor Fitzgerald reissued an "overweight" rating. In December 2025, the first patient was dosed in Australia for the HERO Phase 3 trial, and CEO Tien-Li Lee and CFO Nelson Sun acquired shares. William Blair and Oppenheimer initiated coverage with "outperform" ratings. In January 2026, Raymond James Financial reiterated a "strong-buy" rating, and B. Riley Financial started coverage with a "buy" rating, but the stock tumbled nearly 10% on the same day. In February 2026, Aardvark Therapeutics' share price rose 12%. Overall, the stock has seen a 0.48% increase over the past six months.

Information directly detailing demand seasonality for Aardvark Therapeutics' specific products and services is not available. As a clinical-stage biopharmaceutical company, its revenue generation is primarily tied to clinical development milestones, potential partnerships, and eventual product commercialization, rather than direct consumer demand with typical seasonal fluctuations. However, implied volatility for AARD stock has historically tended to rise the most in January.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics that activate innate homeostatic pathways to treat metabolic diseases. Their lead product candidate, ARD-101, is in Phase 3 clinical trials for hyperphagia associated with Prader-Willi Syndrome (PWS) and is also being evaluated for hyperphagia linked to acquired hypothalamic obesity. The company is also developing ARD-201, which is in Phase 1 clinical trials for the treatment of obesity. Aardvark Therapeutics was incorporated in 2017 and is headquartered in San Diego, California, operating within the Health Technology sector and the Pharmaceuticals: Major industry, specifically focusing on Drug Discovery.

Aardvark Therapeutics, Inc. is headquartered in San Diego, California, United States. Clinical trials, such as the HERO Phase 3 trial for Prader-Willi Syndrome, have included dosing patients in Australia, but broader details about a global geographic footprint are not extensively detailed.

Aardvark Therapeutics has a news sentiment score of 1.43, suggesting a generally positive brand reputation. Positive analyst coverage, the initiation of the Phase 3 clinical trial for ARD-101, FDA alignment to broaden trial eligibility, presentations at investor conferences, beating analyst EPS expectations, and insider buying activity have likely positively affected the company's reputation. The entry of a competitor, Vykat, into the PWS market could create commercial uncertainty.

Aardvark Therapeutics, Inc. has 109 institutional owners and shareholders, holding a total of 9,627,495 shares. Decheng Capital LLC is the largest shareholder with 18% ownership. Other major institutional owners include Citadel Advisors Llc, Laurion Capital Management LP, and Vanguard Group Inc. Individual insiders hold 14.74% of the shares outstanding. CEO Tien-Li Lee is a significant individual shareholder and the third-largest shareholder overall, while CFO Nelson Sun also holds shares.